ArticleDiscover oncology2025
Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBladder cancer is a prevalent malignant tumor in the urinary system, ranking tenth among malignant tumors globally. Currently, the primary treatment methods include surgery, chemotherapy, immunotherapy, and emerging neoadjuvant therapies. These treatments have effectively reduced the mortality rate associated with bladder tumors. However, the prognosis for bladder cancer patients remains poor due to the high rates of recurrence, metastasis, and drug resistance. Therefore, identifying the pathological features and tumor immune environment of each patient to develop optimal treatment strategies is an urgent health issue.
methodsWe analyzed a single-cell dataset of bladder cancer to identify key signaling pathways and chromosomal mutations among different subgroups of bladder tumors. Additionally, we sought to identify ligand-receptor pairs between malignant bladder tumor epithelial cells and other cell subgroups. Using the TCGA-BLCA database and COX regression analysis, we screened key ligand-receptor pairs closely related to patient prognosis. We then used LASSO regression analysis to construct a bladder cancer risk prediction model based on these key ligand-receptor pairs (LR.Riskscore). To evaluate the impact of different LR.Riskscores on prognosis and clinical benefits for bladder cancer patients, we used Kaplan-Meier survival curves, risk forest plots, nomograms, and decision curve analysis. We also conducted cellular experiments, including clone formation, CCK8 assays, Transwell migration assays, and scratch assays, to elucidate the important cellular role of the key receptor CXCR4 in bladder tumor cells. Finally, we utilized the IMvigor210 bladder cancer immunotherapy dataset to reveal the correlation between the LR.Riskscore risk equation and bladder cancer immunotherapy.
resultsWe constructed a bladder cancer risk prediction model based on key ligand-receptor pairs, including CXCL12_CXCR4, VEGFA_FLT1, PDGFRA_PDGFC, WNT2_SFRP4, and HLA-E_KLRC1. This model effectively predicted the prognosis and immunotherapy responsiveness of bladder cancer patients, significantly enhancing clinical benefits compared to conventional clinical features. Additionally, our cellular experiments confirmed the oncogenic role of the key receptor CXCR4 in bladder cancer.
conclusionOur risk prediction model significantly improves the evaluation of prognosis and the prediction of immunotherapy responsiveness in bladder cancer patients. This advancement promotes the development of precise, individualized treatment strategies for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.